194 related articles for article (PubMed ID: 33716483)
1. Guideline Concordance With Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience.
Mir NA; Hull O; Bothwell S; Das D
Fed Pract; 2021 Feb; 38(2):74-78. PubMed ID: 33716483
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study.
Moore AM; Nooruddin Z; Reveles KR; Datta P; Whitehead JM; Franklin K; Alkadimi M; Williams MH; Williams RA; Smith S; Reichelderfer R; Cotarla I; Brannman L; Frankart A; Mulrooney T; Hsieh K; Simmons DJ; Jones X; Frei CR
Curr Oncol; 2023 Sep; 30(9):8411-8423. PubMed ID: 37754526
[TBL] [Abstract][Full Text] [Related]
3. Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.
Moore AM; Nooruddin Z; Reveles KR; Koeller JM; Whitehead JM; Franklin K; Datta P; Alkadimi M; Brannman L; Cotarla I; Frankart AJ; Mulrooney T; Jones X; Frei CR
Oncologist; 2023 Sep; 28(9):804-811. PubMed ID: 37335901
[TBL] [Abstract][Full Text] [Related]
4. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
Front Oncol; 2021; 11():744956. PubMed ID: 34650927
[TBL] [Abstract][Full Text] [Related]
5. Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
Borghetti P; Volpi G; Facheris G; Cossali G; Mataj E; La Mattina S; Singh N; Imbrescia J; Bonù ML; Tomasini D; Vitali P; Greco D; Bezzi M; Melotti F; Benvenuti M; Borghesi A; Grisanti S; Buglione di Monale E Bastia M
Front Oncol; 2023; 13():1208204. PubMed ID: 37469420
[TBL] [Abstract][Full Text] [Related]
6. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
7. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Shaverdian N; Offin MD; Rimner A; Shepherd AF; Wu AJ; Rudin CM; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Mar; 144():101-104. PubMed ID: 31786421
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
[TBL] [Abstract][Full Text] [Related]
9. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.
Lau SCM; Ryan M; Weiss J; Fares AF; Garcia M; Schmid S; Kuang S; Kelly D; Tsao MS; Bradbury PA; Cho BCJ; Sun A; Raman S; Hope A; Giuliani M; Lok BH; Bezjak A; Liu G; Leighl NB; Shepherd FA; Sacher AG
JTO Clin Res Rep; 2021 Dec; 2(12):100251. PubMed ID: 34917991
[TBL] [Abstract][Full Text] [Related]
12. Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC.
Kuge T; Shiroyama T; Tamiya A; Tamiya M; Kanazu M; Kinehara Y; Tanaka T; Morimura O; Taniguchi Y; Niki T; Tetsumoto S; Hayashi K; Nishino K; Nagatomo I; Kumanogoh A
JTO Clin Res Rep; 2023 May; 4(5):100505. PubMed ID: 37284296
[TBL] [Abstract][Full Text] [Related]
13. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer.
Sankar K; Bryant AK; Strohbehn GW; Zhao L; Elliott D; Moghanaki D; Kelley MJ; Ramnath N; Green MD
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158881
[TBL] [Abstract][Full Text] [Related]
14. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
15. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
16. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
17. Variations in patterns of prescribing durvalumab in stage III lung cancer: a survey of Australian Medical Oncologists.
Nindra U; Bray V; Karikios D; Shafiei M; Subramaniam S; Ding P; Kao S; Pal A
Oncology; 2024 Jan; ():. PubMed ID: 38232722
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
Diamond BH; Belani N; Masel R; DeCarli K; DiPetrillo T; Hepel JT; Azzoli CG; Khurshid H; Abbas A; Koffer PP
Adv Radiat Oncol; 2023; 8(2):101130. PubMed ID: 36845618
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
